<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1185</ReferenceId>
        <DateLastUpdated>2020-10-11-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15213154</PubmedId>
            <Abstract>Development of Vibrio cholerae lipopolysaccharide (LPS) as a cholera vaccine immunogen is justified by the correlation of vibriocidal anti-LPS response with immunity. Two V. cholerae O1 LPS serotypes, Inaba and Ogawa, are associated with endemic and pandemic cholera. Both serotypes induce protective antibody following infection or vaccination. Structurally, the LPSs that define the serotypes are identical except for the terminal perosamine moiety, which has a methoxyl group at position 2 in Ogawa but a hydroxyl group in Inaba. The terminal sugar of the Ogawa LPS is a protective B-cell epitope. We chemically synthesized the terminal hexasaccharides of V. cholerae serotype Ogawa, which comprises in part the O-specific polysaccharide component of the native LPS, and coupled the oligosaccharide at different molar ratios to bovine serum albumin (BSA). Our initial studies with Ogawa immunogens showed that the conjugates induced protective antibody. We hypothesized that antibodies specific for the terminal sugar of Inaba LPS would also be protective. Neoglycoconjugates were prepared from synthetic Inaba oligosaccharides (disaccharide, tetrasaccharide, and hexasaccharide) and BSA at different levels of substitution. BALB/c mice responded to the Inaba carbohydrate (CHO)-BSA conjugates with levels of serum antibodies of comparable magnitude to those of mice immunized with Ogawa CHO-BSA conjugates, but the Inaba-specific antibodies (immunoglobulin M [IgM] and IgG1) were neither vibriocidal nor protective in the infant mouse cholera model. We hypothesize that the anti-Inaba antibodies induced by the Inaba CHO-BSA conjugates have enough affinity to be screened via enzyme-linked immunosorbent assay but not enough to be protective in vivo.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>4090-101</ArticlePages>
            <ArticleTitle>Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Meeks</LastName>
                    <ForeName>Michael D</ForeName>
                </Author>
                <Author>
                    <LastName>Saksena</LastName>
                    <ForeName>Rina</ForeName>
                </Author>
                <Author>
                    <LastName>Ma</LastName>
                    <ForeName>Xingquan</ForeName>
                </Author>
                <Author>
                    <LastName>Wade</LastName>
                    <ForeName>Terri K</ForeName>
                </Author>
                <Author>
                    <LastName>Taylor</LastName>
                    <ForeName>Ronald K</ForeName>
                </Author>
                <Author>
                    <LastName>Kov√°c</LastName>
                    <ForeName>Pavol</ForeName>
                </Author>
                <Author>
                    <LastName>Wade</LastName>
                    <ForeName>William F</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Microbiology and Immunology, Dartmouth Medical School, 630 W. Borwell Bldg., Lebanon, NH 03756, USA.</Affiliations>
            <ArticleChemicalList>Antibodies;O Antigens;Serum Albumin, Bovine</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies(immunology); Female; Mice; O Antigens(immunology; metabolism); Serum Albumin, Bovine(metabolism); Vibrio cholerae O1(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>72</Volume>
                <Issue>7</Issue>
                <Title>Infection and immunity</Title>
                <Issn>0019-9567</Issn>
                <MedlineTa>Infect Immun</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Inaba O-SP disaccharide</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalNonSequenceMolecule>
                        <ChemicalType>Carbohydrate fragment</ChemicalType>
                        <Molecule>
                            <ChEBIId>CHEBI:59298</ChEBIId>
                        </Molecule>
                        <SourceMolecule>
                            <ChEBIId>CHEBI:16412</ChEBIId>
                        </SourceMolecule>
                        <SourceOrganismId>10000567</SourceOrganismId>
                    </FragmentOfANaturalNonSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>125612</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This carbohydrate unit forms to the O-polysaccharide from V.cholera O1 serotype Inaba LPS.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 3 and 4</LocationOfData>
                        <BCellId>1736269</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalNonSequenceMolecule>
                                            <ChemicalType>Carbohydrate fragment</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:59298</ChEBIId>
                                            </Molecule>
                                            <SourceMolecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000567</SourceOrganismId>
                                        </FragmentOfANaturalNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P02769.4</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 10 micrograms (based on CHO weight) of  1:1 conjugate:Ribi mixture.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>This disaccharide, as well as the tetra and hexasaccharides (formed as 2 or 3 repeats of this structure) were used conjugated to BSA (including a linker molecule). Final bleeding was performed 1 wk after final immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <AssayComments>Reactivity against Inaba LPS is high in the IgG1 isotype after 3 immunizations with all the formulation used (hexa-, tetra- or disaccharide immunogens in different CHO/BSA ratios) except for the use of hexasaccharide at a high ratio (19:1 CHO:BSA mol:mol). IgM reactivity and titers are lower than those of IgG1 after 3 immunizations.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>LPS</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:16412</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10000567</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table I</LocationOfData>
                        <BCellId>1736276</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalNonSequenceMolecule>
                                            <ChemicalType>Carbohydrate fragment</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:59298</ChEBIId>
                                            </Molecule>
                                            <SourceMolecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000567</SourceOrganismId>
                                        </FragmentOfANaturalNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P02769.4</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 10 micrograms (based on CHO weight) of  1:1 conjugate:Ribi mixture.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>This disaccharide, as well as the tetra and hexasaccharides (formed as 2 or 3 repeats of this structure) were used conjugated to BSA (including a linker molecule). Final bleeding was performed 1 wk after final immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>239</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>None of the formulations used (with hexa- tetra- or disaccharide immunogens conjugated at different ratios with BSA) induces antibodies that show in vitro bactericidal effect against Ogawa strain O395 bacteria.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000568</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 6</LocationOfData>
                        <BCellId>1736277</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalNonSequenceMolecule>
                                            <ChemicalType>Carbohydrate fragment</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:59298</ChEBIId>
                                            </Molecule>
                                            <SourceMolecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000567</SourceOrganismId>
                                        </FragmentOfANaturalNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P02769.4</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 10 micrograms (based on CHO weight) of  1:1 conjugate:Ribi mixture.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>This disaccharide, as well as the tetra and hexasaccharides (formed as 2 or 3 repeats of this structure) were used conjugated to BSA (including a linker molecule). Final bleeding was performed 1 wk after final immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>None of the formulations used (with hexa- tetra- or disaccharide immunogens conjugated at different ratios with BSA) induces antiboodies that show capacity to bind to the surface of Inaba bacteria, as shown by labelling the bacteria in solution and resolving the bound species in an immunoblot.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Child</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>243277</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 3 and 4</LocationOfData>
                        <BCellId>16735</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalNonSequenceMolecule>
                                            <ChemicalType>Carbohydrate fragment</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:59298</ChEBIId>
                                            </Molecule>
                                            <SourceMolecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000567</SourceOrganismId>
                                        </FragmentOfANaturalNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P02769.4</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 10 micrograms (based on CHO weight) of  1:1 conjugate:Ribi mixture.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>This disaccharide, as well as the tetra and hexasaccharides (formed as 2 or 3 repeats of this structure) were used conjugated to BSA (including a linker molecule). Final bleeding was performed 1 wk after final immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Reactivity against Inaba LPS is high in the IgG1 isotype after 3 immunizations with all the formulation used (hexa-, tetra- or disaccharide immunogens in different CHO/BSA ratios) except for the use of hexasaccharide at a high ratio (19:1 CHO:BSA mol:mol). IgM reactivity and titers are lower than those of IgG1 after 3 immunizations.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>LPS</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:16412</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10000567</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1736270</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalNonSequenceMolecule>
                                            <ChemicalType>Carbohydrate fragment</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:59298</ChEBIId>
                                            </Molecule>
                                            <SourceMolecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000567</SourceOrganismId>
                                        </FragmentOfANaturalNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P02769.4</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 10 micrograms (based on CHO weight) of  1:1 conjugate:Ribi mixture.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>This disaccharide, as well as the tetra and hexasaccharides (formed as 2 or 3 repeats of this structure) were used conjugated to BSA (including a linker molecule). Final bleeding was performed 1 wk after final immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Cross-reactive recognition against Ogawa LPS is similar to that of the parental Inaba LPS for all the immunogens used (hexa-, tetra- or disaccharide immunogens in different CHO/BSA ratios).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>LPS</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:16412</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10000568</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table I, Figure 5</LocationOfData>
                        <BCellId>16736</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalNonSequenceMolecule>
                                            <ChemicalType>Carbohydrate fragment</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:59298</ChEBIId>
                                            </Molecule>
                                            <SourceMolecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000567</SourceOrganismId>
                                        </FragmentOfANaturalNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P02769.4</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 10 micrograms (based on CHO weight) of  1:1 conjugate:Ribi mixture.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>This disaccharide, as well as the tetra and hexasaccharides (formed as 2 or 3 repeats of this structure) were used conjugated to BSA (including a linker molecule). Final bleeding was performed 1 wk after final immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>239</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>None of the formulations used (with hexa- tetra- or disaccharide immunogens conjugated at different ratios with BSA) induces antiboodies that show in vitro or in vivo bactericidal effect against Inaba strains 569B, N16961 or El Tor Inaba strain N16961.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000567</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>1736271</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalNonSequenceMolecule>
                                            <ChemicalType>Carbohydrate fragment</ChemicalType>
                                            <Molecule>
                                                <ChEBIId>CHEBI:59298</ChEBIId>
                                            </Molecule>
                                            <SourceMolecule>
                                                <ChEBIId>CHEBI:16412</ChEBIId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000567</SourceOrganismId>
                                        </FragmentOfANaturalNonSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <GenBankId>P02769.4</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>9913</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Ribi</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>3 doses 2 wks apart with 10 micrograms (based on CHO weight) of  1:1 conjugate:Ribi mixture.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>This disaccharide, as well as the tetra and hexasaccharides (formed as 2 or 3 repeats of this structure) were used conjugated to BSA (including a linker molecule). Final bleeding was performed 1 wk after final immunization.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <AssayComments>Cross-reactive recognition against Ogawa LPS is similar to that of the parental Inaba LPS for all the immunogens used (hexa-, tetra- or disaccharide immunogens in different CHO/BSA ratios).</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>LPS</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Taxonomic Sibling</EpitopeRelation>
                                <Object>
                                    <AccessionNonSequenceMolecule>
                                        <ChemicalType>Glycolipid</ChemicalType>
                                        <Molecule>
                                            <ChEBIId>CHEBI:16412</ChEBIId>
                                        </Molecule>
                                        <SourceOrganismId>10000568</SourceOrganismId>
                                    </AccessionNonSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

